Latest Adherium (ASX:ADR) News

Adherium Limited has raised A$0.35 million through an institutional placement, supplementing its recent entitlement offer to strengthen its financial position and support growth initiatives.

Adherium Limited reports a robust 30% increase in US remote patient monitoring users and closes a $4.5 million capital raise, positioning itself for accelerated growth under new leadership.

Adherium Limited has appointed seasoned medtech executive Dawn Bitz as CEO to spearhead the expansion of its Hailie® respiratory monitoring platform, with a strong focus on the US market.

Adherium Limited has successfully completed a $4.49 million entitlement offer, combining institutional and retail components, to fund expansion of its Hailie® digital respiratory monitoring platform.

Adherium Limited has announced a partially underwritten entitlement offer aiming to raise approximately A$4.5 million through the issuance of new shares and options at a significant discount. The capital raise is designed to accelerate patient onboarding and product development for its respiratory monitoring technology.

Adherium Limited has successfully closed the institutional portion of its entitlement offer, increasing the raise to $4.492 million due to robust demand. The company now invites retail shareholders to participate as it advances its digital respiratory health solutions.

Adherium Limited has announced an accelerated non-renounceable entitlement offer to raise approximately A$4 million, issuing new shares and options to fund expansion and product development. The offer includes a Top-Up Facility and is partially underwritten, signaling a strategic push to scale its respiratory monitoring technology.

Adherium Limited is raising up to $4 million through a partially underwritten entitlement offer to expand its US digital health platform and recruit key personnel. The capital raise supports scaling patient onboarding and advancing its FDA-cleared smart inhaler technology.

Adherium Limited has locked in $900,000 through convertible notes to fund the expansion of its Hailie® Smartinhaler® platform in the US, pending shareholder approval at the upcoming AGM.

Adherium Limited reports a surge in US commercial patients for its Hailie Smartinhaler platform, alongside strategic hires and a new product launch compatible with AstraZeneca inhalers, underpinning plans for a capital raise.

Adherium reports strong patient adoption and new US partnerships, positioning for significant expansion in 2025 with a target of 9,000 active users and entry into the Pharmacy Benefit Management sector.